Mesenchymal stromal cells: Biological properties and clinical prospects

• Published in: Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine Vol. 18; no. 1; p. 1
• Main Authors: Roux, S, Leotot, J, Chevallier, N, Bierling, P, Rouard, H
• Format: Journal Article
• Language: French
• Published: France 01-02-2011
• Subjects: Adult; Animals; Antigens, Differentiation - immunology; Autoimmune Diseases - surgery; Autoimmunity; Cell Line; Cell Lineage; Cell Movement; Encephalomyelitis, Autoimmune, Experimental - immunology; Encephalomyelitis, Autoimmune, Experimental - surgery; Fetal Stem Cells - cytology; Graft vs Host Disease - surgery; Humans; Immunocompetence; Immunosuppression; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - immunology; Mice; Myocardial Infarction - surgery; Regeneration - physiology
• ISSN: 1953-8022
• DOI: 10.1016/j.tracli.2011.01.001

Mesenchymal stromal cells are defined as non-hematopoietic progenitors characterised by their adherence to plastic in culture, their expression of non-specific markers and their differentiation potential into cells of mesodermic lineage. Resident in numerous tissues, mesenchymal stromal cells are now available from several sources, including both adult and foetal tissues. After their administration, mesenchymal stromal cells preferentially migrate to injured tissues. Mesenchymal stromal cells have therapeutic effects in numerous animal models of tissue injury by a mechanism not yet clearly understood. Mechanisms likely involved in repair can be the production of paracrine, anti-inflammatory and anti-apoptotic factors, as well as cell replacement by their differentiation potential. Mesenchymal stromal cells possess immunosuppressive properties on both innate and adaptative immunity in vitro and in animal models of autoimmunity. Currently their immunosuppressive properties allow testing of mesenchymal stromal cells in allogenic context, although this use requires further investigations. Mesenchymal stromal cells can be isolated and expanded in vitro in clinical grade conditions. They represent a promising candidate for the cellular therapy of diseases, such as acute myocardial infarction, diabetes, graft versus host disease or neurodegenerative diseases. Critical points including the standardization of production and long term toxicity have to be resolved before their large scale use in clinical conditions.